Loss of plexin‑B3 in hepatocellular carcinoma

Liu,Yuwu; Wu,Chang; Wang,Ying; Wen,Sailan; Wang,Junpu; Chen,Zhihong; He,Qiongqiong; Feng,Deyun

doi:10.3892/etm.2015.2243

Loss of plexin‑B3 in hepatocellular carcinoma

Authors:
- Yuwu Liu
- Chang Wu
- Ying Wang
- Sailan Wen
- Junpu Wang
- Zhihong Chen
- Qiongqiong He
- Deyun Feng
View Affiliations

Affiliations: Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Department of Pathology, Shenzhen Sixth People's Hospital (Nanshan Hospital), Shenzhen, Guangdong 518052, P.R. China
Published online on: January 30, 2015 https://doi.org/10.3892/etm.2015.2243
Pages: 1247-1252

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Plexins are the primary receptors of semaphorins, and participate in the majority of intracellular pathways triggered by semaphorins, including the regulation of cell adhesion and the motility of numerous cell types. Recently, several studies have reported that plexins can significantly affect different aspects of cancer cell biology, and the aberrant expression of plexins has been observed in a wide variety of tumor types. However, the expression and role of plexin‑B3 in hepatocellular carcinoma (HCC) is yet to be investigated. In the present study, plexin‑B3 expression was measured in 14 paired HCC samples and the corresponding adjacent non‑cancerous tissue by quantitative polymerase chain reaction and western blot analysis. The results indicated that the mRNA and protein expression levels of plexin‑B3 were downregulated in HCC samples when compared with the corresponding adjacent non‑cancerous tissue. In order to elucidate the correlation between clinicopathological data and the expression of plexin‑B3 in patients with HCC, 84 HCC archived specimens were analyzed by immunohistochemistry (IHC). The IHC results revealed that the protein expression level of plexin‑B3 was lower in the HCC samples compared with the corresponding adjacent non‑cancerous tissue, and plexin‑B3 underexpression was correlated with the patient gender and tumor size. In conclusion, these results indicated that loss of plexin‑B3 in HCC may be of predictive value for the occurrence and progression of HCC. Thus, plexin‑B3 may be a promising biomarker for the diagnosis and treatment of tumors in the future.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Perz JF, Armstrong GL, Farrington LA, Hutin YJ and Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI
3	Shin JW and Chung YH: Molecular targeted therapy for hepatocellular carcinoma: current and future. World J Gastroenterol. 19:6144–6155. 2013. View Article : Google Scholar : PubMed/NCBI
4	Trevisani F, Cantarini MC, Wands JR and Bernardi M: Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis. 29:1299–1305. 2008. View Article : Google Scholar : PubMed/NCBI
5	Yang Y, Nagano H, Ota H, et al: Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 141:196–202. 2007. View Article : Google Scholar : PubMed/NCBI
6	Kruger RP, Aurandt J and Guan KL: Semaphorins command cells to move. Nat Rev Mol Cell Biol. 6:789–800. 2005. View Article : Google Scholar : PubMed/NCBI
7	Yazdani U and Terman JR: The semaphorins. Genome Biol. 7:2112006. View Article : Google Scholar : PubMed/NCBI
8	Mann F, Chauvet S and Rougon G: Semaphorins in development and adult brain: Implication for neurological diseases. Prog Neurobiol. 82:57–79. 2007. View Article : Google Scholar : PubMed/NCBI
9	Tamagnone L: Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer. Cancer Cell. 22:145–152. 2012. View Article : Google Scholar : PubMed/NCBI
10	Tamagnone L, Artigiani S, Chen H, et al: Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell. 99:71–80. 1999. View Article : Google Scholar : PubMed/NCBI
11	Rehman M and Tamagnone L: Semaphorins in cancer: biological mechanisms and therapeutic approaches. Semin Cell Dev Biol. 24:179–189. 2013. View Article : Google Scholar
12	Zhou Y, Gunput RA and Pasterkamp RJ: Semaphorin signaling: progress made and promises ahead. Trends Biochem Sci. 33:161–170. 2008. View Article : Google Scholar : PubMed/NCBI
13	Sadanandam A, Varney ML and Singh RK: Identification of semaphorin 5A interacting protein by applying apriori knowledge and peptide complementarity related to protein evolution and structure. Genomics Proteomics Bioinformatics. 6:163–174. 2008. View Article : Google Scholar
14	Artigiani S, Conrotto P, Fazzari P, et al: Plexin-B3 is a functional receptor for semaphorin 5A. EMBO Rep. 5:710–714. 2004. View Article : Google Scholar : PubMed/NCBI
15	Hartwig C, Veske A, Krejcova S, Rosenberger G and Finckh U: Plexin B3 promotes neurite outgrowth, interacts homophilically, and interacts with Rin. BMC Neurosci. 6:532005. View Article : Google Scholar : PubMed/NCBI
16	Li X and Lee AY: Semaphorin 5A and plexin-B3 inhibit human glioma cell motility through RhoGDIalpha-mediated inactivation of Rac1 GTPase. J Biol Chem. 285:32436–32445. 2010. View Article : Google Scholar : PubMed/NCBI
17	Wong OG, Nitkunan T, Oinuma I, et al: Plexin-B1 mutations in prostate cancer. Proc Natl Acad Sci USA. 104:19040–19045. 2007. View Article : Google Scholar : PubMed/NCBI
18	Tong Y, Hota PK, Hamaneh MB and Buck M: Insights into oncogenic mutations of plexin-B1 based on the solution structure of the Rho GTPase binding domain. Structure. 16:246–258. 2008. View Article : Google Scholar : PubMed/NCBI
19	Balakrishnan A, Penachioni JY, Lamba S, et al: Molecular profiling of the ‘plexinome’ in melanoma and pancreatic cancer. Hum Mutat. 30:1167–1174. 2009. View Article : Google Scholar : PubMed/NCBI
20	Pan GQ, Ren HZ, Zhang SF, Wang XM and Wen JF: Expression of semaphorin 5A and its receptor plexin B3 contributes to invasion and metastasis of gastric carcinoma. World J Gastroenterol. 15:2800–2804. 2009. View Article : Google Scholar : PubMed/NCBI
21	Edmondson HA and Steiner PE: Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
22	Wittekind C: Pitfalls in the classification of liver tumors. Pathologe. 27:289–293. 2006.(In German). View Article : Google Scholar : PubMed/NCBI
23	Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG and Morrow M: TNM classification of Malignant Tumors. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed. Springer; New York, NY: pp. 1332002
24	Casazza A, Fazzari P and Tamagnone L: Semaphorin signals in cell adhesion and cell migration: functional role and molecular mechanisms. Adv Exp Med Biol. 600:90–108. 2007. View Article : Google Scholar : PubMed/NCBI
25	Kantor DB, Chivatakarn O, Peer KL, et al: Semaphorin 5A is a bifunctional axon guidance cue regulated by heparan and chondroitin sulfate proteoglycans. Neuron. 44:961–975. 2004. View Article : Google Scholar : PubMed/NCBI
26	Pan G, Zhu Z, Huang J, et al: Semaphorin 5A promotes gastric cancer invasion/metastasis via urokinase-type plasminogen activator/phosphoinositide 3-kinase/protein kinase B. Dig Dis Sci. 58:2197–2204. 2013. View Article : Google Scholar : PubMed/NCBI
27	Pan G, Zhang X, Ren J, et al: Semaphorin 5A, an axon guidance molecule, enhances the invasion and metastasis of human gastric cancer through activation of MMP9. Pathol Oncol Res. 19:11–18. 2013. View Article : Google Scholar
28	Sadanandam A, Sidhu SS, Wullschleger S, et al: Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation. Br J Cancer. 107:501–507. 2012. View Article : Google Scholar : PubMed/NCBI
29	Sadanandam A, Varney ML, Singh S, et al: High gene expression of semaphorin 5A in pancreatic cancer is associated with tumor growth, invasion and metastasis. Int J Cancer. 127:1373–1383. 2010. View Article : Google Scholar : PubMed/NCBI